Table 1.
Cohort demographics, by specialty pharmacy type
| Characteristic | On-site intensive specialty pharmacy (n = 184) | Off-site specialty pharmacy (n = 35) |
|---|---|---|
| Age, y-median (IQR) | 59 (53–62) | 57 (52.5–61) |
| Women, n (%) | 57 (31.0) | 8 (22.9) |
| Ethnicity, n (%) | ||
| Black | 79 (42.9) | 15 (42.9) |
| White | 56 (30.4) | 14 (40.0) |
| Hispanic | 34 (18.5) | 1 (2.9) |
| Asian | 7 (3.8) | 2 (5.7) |
| Other/unknown | 8 (4.3) | 3 (8.6) |
| Insurance, n (%) | ||
| Private | 50 (27.2) | 21 (60.0) |
| Medicaid | 63 (34.2) | 9 (25.7) |
| Medicare | 27 (14.7) | 3 (8.6) |
| Medicare and medicaid | 33 (17.9) | 2 (5.7) |
| Free care | 15 (8.2) | 0 (0.0) |
| Genotype, n (%) | ||
| 1 | 168 (91.3) | 33 (94.3) |
| 2 | 4 (2.2) | 1 (2.9) |
| 3 | 5 (2.7) | 0 |
| 4 | 5 (2.7) | 0 |
| 5 | 0 | 0 |
| 6 | 2 (1.1) | 1 (2.9) |
| Cirrhosis, n (%) | 93 (50.5) | 21 (60.0) |
| Decompensated cirrhosis | 28/86 (32.6) | 6/21 (28.6) |
| MELD-median (IQR) | 7 (6–7.9) | 7 (6–7.5) |
| Prior treatment, n (%) | ||
| Treatment-naive | 125/181 (69.1) | 18 (51.4) |
| Non-responder | 21/181 (11.6) | 6 (17.1) |
| Relapsed | 20/181 (11.0) | 2 (5.7) |
| Stopped due to adverse effects | 15/181 (8.3) | 7 (20.0) |
| PPI use (any dose), n (%) | 50 (27.2) | 8 (22.9) |
| Opioid maintenance therapy, n (%) | 30 (16.3%) | 4 (11.4%) |
IQR interquartile range, MELD model for end-stage liver disease, PPI proton-pump inhibitor